Search Results

227 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 45

    Meta-analysis of two biomarkers of exposure of tobacco products

    AYALA-FIERRO F.(1); ELAMIN A.(2); FROST-PINEDA K.(3); JIN T.(3); PRASAD G.L.(3); SARKAR M.(4); SCHMIDT E.(3); VERRON T.(5)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) Altria Client Services LLC, Richmond, VA, U.S.A.; (5) SEITA - Imperial Brands, Paris, France
    In the context of tobacco products, broadly two types of biomarkers exist, biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH). BoE measure exposure to tobacco constituents, e.g. carbon monoxide (CO) and nicotine equivalents (NEQs). The ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 47

    A high-throughput and sensitive bioanalytical method for quantification of nicotine and cotinine in rat/mouse plasma using reversed-phase liquid chromatography–tandem mass spectrometry and its application in inhalation study sample analysis

    SAXENA A.(1); ZHANG Chunyan(1); CIPUTRA T.(1); CHNG Yun Xuan(1); PHILLIPS B.(1); VANSCHEEUWIJCK P.(2)
    (1) PMI R&D, Philip Morris International Research Laboratories Pte. Ltd., Singapore; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Nicotine and cotinine are used as primary biomarkers to estimate the exposure of reduced-risk products, such as e-liquids/heated tobacco products, in comparison with cigarettes. The objective of this study was to develop and validate a method per current ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 40 (also presented at TSRC 2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); SKOWRONEK A.(3); HOENG J.(2); PEITSCH M.C.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Philip Morris Products S.A., R&D, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, U.S.A.
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion by ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 41

    Sharing and reusing data: toxicology assessment meta-analysis of various e-liquids and heat-not-burn platforms with INTERVALS datasets

    STAN A.; BOUÉ S.; HOENG J.; PEITSCH M.C.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Extensive scientific studies are conducted to assess the relative risks of various candidate modified risk tobacco products compared with those of smoking cigarettes. As the scientific community conducts such assessments for diverse products and in a ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in vitro ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 57

    Cross-cultural equivalence of the ABOUT™–Perceived Risk instrument in seven languages

    CHREA C.(1); CANO S.(2); SALZBERGER T.(3); MAINY N.(1); ACQUADRO C.(4); POPIELNICKI A.(5); WEITKUNAT R.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Modus Outcomes, Letchworth Garden City, U.K.; (3) University of Economics and Business, Vienna, Austria; (4) Mapi Research Trust, ICON plc, Lyon, France; (5) TransPerfect, Linguistic Validation Group, Boston, MA, U.S.A.
    The risk of smoking has long been well understood by consumers. However, it is important to measure the perceived risks by consumers of novel smoke-free alternatives to cigarettes. The ABOUT™–Perceived Risk instrument was developed to allow the ...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco products ...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 59

    A novel repository for consumer reported outcome measures in tobacco research: development, implementation and evolution from 2016 to date

    CLERC E.(1); MAINY N.(1); PERRET C.(2); ACQUADRO C.(3); BACSO A.(1); BINGGELI P.(1); CHREA C.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Mapi Research Trust, Lyon, France; (3) ICON plc, Lyon, France
    The consumer reported outcome measures Repository is a measurement instrument knowledge base developed by Mapi Research Trust (MRT) for Philip Morris International (PMI) in June 2016. It enables PMI researchers to identify and select measures to assess ...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STW 02

    Contemporary high-content screening approaches to assess the biological impact of single compounds and complex mixtures in vitro

    FRENTZEL S.(1); THORNE D.(2); MARESCOTTI D.(1); TAYLOR M.(2); BOVARD D.(1); MORELLI M.(1); MATHIS C.(1); HOENG J.(1); GACA M.(2); PEITSCH M.C.(1); PROCTOR C.J.(2)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) British American Tobacco, R&D Centre, Southampton, U.K.
    High-content screening (HCS) is an automated image-based screening technology that allows analysing macroscopically the biological impact of single compounds or complex mixtures on cells growing in multi-well culture dishes. The technology involves ...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STW 04

    Multi-organ-on-a-chip platforms to assess the biological impact of toxicants as well as PBPK properties in vitro

    FRENTZEL S.; BOVARD D.; SANDOZ A.; LUETTICH K.; HOENG J.; PEITSCH M.C.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    The merging of three-dimensional (3D) organotypic in vitro models with multi-organ-on-a-chip (MOC) technology has taken in vitro assessment of chemicals to an unprecedented level. By connecting multiple 3D organotypic models, MOCs enable the study of ...